Estrogen receptor(ER) is a vital biomarker in the development and development of breast cancer, and its status has great clinical value in clinical treatment strategy, endocrine therapy efficacy prediction, and breast...Estrogen receptor(ER) is a vital biomarker in the development and development of breast cancer, and its status has great clinical value in clinical treatment strategy, endocrine therapy efficacy prediction, and breast cancer prognosis. By specifically combining <sup>18</sup>F-FES with ER, <sup>18</sup>F-FES PET/CT imaging uses standard uptake value(SUV) to semi-quantitatively reflect the distribution of ER and its biological activity in patients, and assesses the expression of ER in breast cancer patients about primary and metastases before or after treatment, to provide a basis for personalized treatment of breast cancer. In this review, we will review the imaging principles of a new ER detection method <sup>18</sup>F-FES PET/CT, and the research progress in the clinical application of breast cancer, and compare its diagnostic and treatment value with non-specific tumor imaging <sup>18</sup>F-FDG PET/CT in breast cancer.展开更多
转镜调Q无插入损耗,是获得窄脉冲、高峰值功率输出激光的直接方式。纳秒脉冲需要使用高速转镜调Q,并精准控制电机转速与氙灯放电延时,以使激光介质上能级粒子数反转最大,获得最大激光能量输出。本文设计了以Arduino mega 2560单片机为...转镜调Q无插入损耗,是获得窄脉冲、高峰值功率输出激光的直接方式。纳秒脉冲需要使用高速转镜调Q,并精准控制电机转速与氙灯放电延时,以使激光介质上能级粒子数反转最大,获得最大激光能量输出。本文设计了以Arduino mega 2560单片机为核心的高速转镜调Q控制系统,通过精确单片机解析串口屏指令控制激光电源的充放电和高速电机启停,同时通过对转镜脉冲信号整合降频控制氙灯放电时刻,实现对延迟时间的精准控制,实现了灯泵Er,Cr:YSGG激光纳秒窄脉冲调Q输出。在5 Hz重复频率下,转镜转速为650 r/s时,获得的最高单脉冲激光能量为45.7 mJ、脉冲宽度为86.2 ns,相应的峰值功率为530.2 kW。展开更多
文摘Estrogen receptor(ER) is a vital biomarker in the development and development of breast cancer, and its status has great clinical value in clinical treatment strategy, endocrine therapy efficacy prediction, and breast cancer prognosis. By specifically combining <sup>18</sup>F-FES with ER, <sup>18</sup>F-FES PET/CT imaging uses standard uptake value(SUV) to semi-quantitatively reflect the distribution of ER and its biological activity in patients, and assesses the expression of ER in breast cancer patients about primary and metastases before or after treatment, to provide a basis for personalized treatment of breast cancer. In this review, we will review the imaging principles of a new ER detection method <sup>18</sup>F-FES PET/CT, and the research progress in the clinical application of breast cancer, and compare its diagnostic and treatment value with non-specific tumor imaging <sup>18</sup>F-FDG PET/CT in breast cancer.